Related to this topic: Support | Patient+ | UK Guidelines | News | Weblinks | Poem/Story | Equipment | Books | Your Experience | Other resources | Glossaries
Print options:
Other options:
(what's this?)
PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.
Down's Syndrome
Synonyms: Mongolism, trisomy 21
It is a common genetic disorder characterised by mental retardation, dysmorphic facial features and a host of structural abnormalities. It is so called after John Langdon Haydon Down, an English physician, 1828-1896.
Incidence
One of the commonest genetic disorders, affecting 1 in 800 live births.1,2
- The underlying genetic defect is trisomy 21 in 94% of cases.
- Mosaicism (2.4%) and translocations (3.3%) also occur.
- 75% of these translocations are de novo errors.
- Family history
- Age of mother:
- 1:385 risk at 35
- 1:106 at 40
- 1:30 at 45 years
At birth there are a wide range of associated physical features. Not all babies have typical facies. Frequently the first feature noticed is hypotonia.
Neonatal Features of Down's syndrome (% neonates found with feature)
*highly specific for Down's syndrome |
Soon after birth all babies with Down's syndrome should be assessed for congenital heart disease by echocardiogram.3 They should also have auditory evoked potential testing (before age 6 months) to check for hearing loss,4 and also be checked for congenital cataracts and glaucoma.5
Cardiological Disorders
Commonest cardiac abnormalities are:
- Atrioventricular canal defects (45%)
- Ventricular septal defect (35%);
- Isolated secundum atrial septal defects (8%),
- Isolated persistent patent ductus arteriosus (7%)
- Tetralogy of Fallot (4-6%)
Adult patients, without known congenital heart disease may develop mitral valve prolapse (46%) or aortic regurgitation (17%). A second assessment in early adulthood may be appropriate.
ENT Disorders
Patients with Down's syndrome may have conductive, sensorineural, or mixed hearing loss.
They are more susceptible to otitis media, sinusitis and pharyngitis.
Obstructive sleep apnoea may develop.
Ophthalmological Disorders
Most commonly:
- Cataracts
- Refractive errors (35-76%)
- Strabismus (27-57%)
- Nystagmus (20%)
- Congenital glaucoma
- Keratoconus
Gastrointestinal Disorders
- Oesophageal atresia or tracheo-oesophageal fistula
- Duodenal atresia
- Pyloric stenosis
- Meckel's diverticulum
- Hirschsprung's disease
- Imperforate anus
- Gastro-oesophageal reflux
- Dental problems; delayed and unusual patterns of eruption, missing teeth
- Coeliac disease occurs frequently enough for screening to be recommended
Orthopaedic Disorders
- Atlanto-axial instability (13%). Only 1-2% need treatment.7 This presents as neck pain, limited movements or symptoms/signs suggestive of cord compression. Less specific symptoms e.g. bladder problems, gait abnormalities or clumsiness may also indicate need for further investigation.
- Hyperflexibility
- Scoliosis
- Hip dislocation after 2 years
- Patellar subluxation or dislocation
- Foot deformities
Endocrine Disorders
These are common, particularly hypothyroidism. Annual TFT's are indicated.8
Neurological Disorders
- Mental retardation (ranges from severe retardation to "low normal")
- Behavioural problems
- Seizures occur in 5-10%
- In older patients an Alzheimer's type picture develops in >60% of those over 60 years of age.
Haematological Disorders
- Patients have approximately 12x greater risk of infections e.g. pneumonia due to impaired cellular immunity.
- They also have increased risk of acute myeloblastic leukaemia (AML) and acute lymphoblastic leukaemia (ALL), also acute megakaryoblastic leukaemia.
- Polycythaemia and transient myeloproliferative disorder (a self-limiting type of leukaemia which regresses spontaneously by the age of 2 months), may occur in newborns.
- There is a large amount of published research on Downs syndrome screening. It looks at combinations of markers ± ultrasound (Nuchal translucency scans measure the thickness of skin at the nuchal fold at around 10-12 weeks gestation), used in the first or second trimesters. Screening aims to identify women at higher risk, than that predicted on the basis of age alone. If the woman chooses to, after counselling on associated risks, she may proceed to invasive testing e.g. chorionic villus sampling or amniocentesis, to establish fetal karyotype.
- The Integrated test offers the most effective and safe method of screening for women who attend in the first trimester.9 This test comprises Nuchal translucency scanning and pregnancy associated plasma protein-A [PAPP-A] at 11 completed weeks of pregnancy, and alpha-fetoprotein, unconjugated oestriol [uE3], free beta or total human chorionic gonadotrophin (hCG) and inhibin-A in the early second trimester. With this method at an 85% detection rate, it has been estimated that there would be six amniocentesis-caused miscarriages of unaffected fetuses per 100,000 women screened, compared with 35 using the Combined test or 45 with the Quadruple test.
- If PAPP-A, hCG and nuchal translucency scanning (NT) are used as a first-trimester screening test, it is commonly referred to as the combined test.
- When hCG and AFP are used between 14 to 20 weeks as a screening test, this is often called the double test.
- If uE3is added to the double test combination, it becomes known as the triple test.
- The addition of inhibin A to the triple test comprises the quadruple test.
- First trimester prenatal screening using a combination of maternal serum biochemistry and fetal nuchal translucency thickness, has been shown to achieve detection rates over 90%.1011
- A Disintegrin And Metalloprotease 12 (ADAM 12) is a glycoprotein synthesised by placenta. It has been shown to be a potential first-trimester maternal serum marker for Down syndrome (DS).12 ADAM 12 and PAPP-A measured at 8-9 weeks and combined with NT and free beta-hCG measured at 12 weeks has been predicted to give a detection rate of 97% at a 5% false-positive rate.
- First trimester screening for trisomy 21 in twin pregnancies is possible and practical using a combination of nuchal translucency thickness and maternal serum biochemistry.13
- Amniocentesis (at 14-16 weeks) is 99.5% accurate. Chorionic villus sampling (CVS) can be performed earlier (10-13 weeks) but accuracy is less (96-98%). Both procedures have an operator specific miscarriage risk.
Document References
- Baird PA, Sadovnick AD; Life tables for Down syndrome. Hum Genet. 1989 Jun;82(3):291-2. [abstract]
- Chen H. Down's Syndrome. e-Medicine; January, 2006
- Down's Syndrome Medical Interest Group; Basic medical surveillance for people with Down's Syndrome : cardiac disease - congenital and acquired (1999)
- Down's Syndrome Medical Interest Group; Basic medical surveillance for people with Down's Syndrome : Hearing Impairment (2000)
- Down's Syndrome Medical Interest Group; Basic medical surveillance for people with Down's Syndrome : ophthalmic problems (1997)
- Saenz RB. Primary Care of Infants and Young Children with Down Syndrome. American Family Physician.; January, 1999.
- Down's Syndrome Medical Interest Group; Basic medical surveillance for people with Down's Syndrome : cervical spine instability (1996)
- Down's Syndrome Medical Interest Group; Basic medical surveillance for people with Down's Syndrome : thyroid disorder (2001)
- Wald NJ, Rodeck C, Hackshaw AK, et al; SURUSS in perspective. Semin Perinatol. 2005 Aug;29(4):225-35. [abstract]
- Spencer K, Spencer CE, Power M, et al; One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG. 2000 Oct;107(10):1271-5. [abstract]
- Spencer K, Spencer CE, Power M, et al; Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG. 2003 Mar;110(3):281-6. [abstract]
- Laigaard J, Spencer K, Christiansen M, et al; ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome. Prenat Diagn. 2006 Oct;26(10):973-9. [abstract]
- Spencer K, Nicolaides KH; Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG. 2003 Mar;110(3):276-80. [abstract]
Internet and Further Reading
- RCOG; Antenatal care: routine care for the healthy pregnant woman - clinical guideline; October 2003
- Down's Syndrome Association. Patient website.
- OMIM. Down's Syndrome
DocID: 2071
Document Version: 21
DocRef: bgp383
Last Updated: 18 Feb 2007
Review Date: 17 Feb 2009
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
Related pages in Patient UK
Your Experience (^ top of page)
Please add your experience about this condition / medicinePatient Support related to this topic (^ top of page)
Down Syndrome Education Trust
Down's Heart Group
Down's Syndrome Association
Down's Syndrome Research Foundation
Down's Syndrome Scotland
Mosaic Down Syndrome UKMedical reference articles in PatientPlus related to this topic (^ top of page)
Amniocentesis
Antenatal Screening for Down's Syndrome
Mental Handicap
Prenatal DiagnosisUK guidelines related to this topic (^ top of page)
Guidelines on Down's SyndromeRecent news items related to this topic (^ top of page)
Pregnant women are forced to go private for Down's syndrome test
Scientists develop risk-free Down's testLinks to other selected websites related to this topic (^ top of page)
Down's SyndromePoems and stories related to this topic (^ top of page)
A Special Kind of LifeOther - Useful resources (^ top of page)
Pictures, diagrams, photos, images, etc.Evidence based medicine
Online textbooks and journals
A-Z of UK Guidelines
A-Z of Online Videos
Medline
Other good health sites
Medical equipment products related to this topic (^ top of page)

Books related to this topic (^ top of page)

Want to search some more? Use the Google Search box below to search our site.

Would you like to try our advanced on-line knowledge support system designed to provide professionals with relevant up to date information about recognition and management of disease or take the Mentor Challenge?
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
